Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Non-Current Debt (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 15 years of Non-Current Debt data on record, last reported at $5.8 million in Q2 2025.

  • For Q2 2025, Non-Current Debt fell 74.67% year-over-year to $5.8 million; the TTM value through May 2025 reached $5.8 million, down 74.67%, while the annual FY2025 figure was $5.8 million, 74.67% down from the prior year.
  • Non-Current Debt reached $5.8 million in Q2 2025 per LFCR's latest filing, down from $8.3 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $164.9 million in Q2 2021 and bottomed at $5.8 million in Q2 2025.
  • Average Non-Current Debt over 5 years is $62.4 million, with a median of $22.9 million recorded in 2024.
  • Peak YoY movement for Non-Current Debt: surged 62.68% in 2021, then crashed 90.77% in 2024.
  • A 5-year view of Non-Current Debt shows it stood at $124.2 million in 2021, then tumbled by 35.91% to $79.6 million in 2022, then increased by 15.69% to $92.1 million in 2023, then plummeted by 90.77% to $8.5 million in 2024, then tumbled by 31.75% to $5.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $5.8 million in Q2 2025, $8.3 million in Q1 2025, and $8.5 million in Q4 2024.